Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 16, 2017

Promius’s sumatriptan meets primary endpoint for migraine

Dr. Reddy’s Laboratories’ subsidiary Promius Pharma has reported positive results from the clinical trial of its ZEMBRACE SymTouch (sumatriptan injection) to treat acute migraine headache.

Dr. Reddy’s Laboratories’ subsidiary Promius Pharma has reported positive results from the clinical trial of its ZEMBRACE SymTouch (sumatriptan injection) to treat acute migraine headache.

EMBRACE SymTouch is a prescription medicine indicated for the treatment of acute headaches with or without aura.

With 268 subjects, the multi-centre, placebo-controlled trial saw 3mg ZEMBRACE SymTouch meet both its primary and various secondary endpoints.

The investigational candidate reduced migraine pain in a high proportion of subjects at two hours after dosing.

“Physicians can consider this low-dose 3mg injectable sumatriptan as an effective treatment option for their migraine patients.”

During the trial, ZEMBRACE SymTouch was found to be well-tolerated, with 33.3% of the participants experiencing treatment-emergent adverse events (TEAE) compared to 13.4% with placebo.

Triptan-related TEAEs were observed in 7.2% of patients within two hours post-dose and the results indicated no treatment-emergent serious adverse events (SAE).

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Study author and Baptist Medical Group headache clinic director Stephen Landy said: “This multi-centre, randomised, double-blind, placebo-controlled trial demonstrates that the 3mg dose of sumatriptan in ZEMBRACE SymTouch provided rapid, complete pain relief in a significant proportion of patients with a low rate of side effects and no SAEs.

“Physicians can consider this low-dose 3mg injectable sumatriptan as an effective treatment option for their migraine patients.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU